Antihypertensive therapy in pregnancy.
Human pregnancy, normally characterized by systemic vasodilation and modest hypotension, can be complicated by underlying maternal hypertension and several unique hypertensive disorders, including pre-eclampsia. Although well-designed and adequately powered clinical trials are critically needed, there have been several recent meta-analyses of this large literature, along with consensus statements and treatment guidelines from three distinct multidisciplinary groups of clinicians and investigators. In this paper we review recent analyses and guidelines, advising on our current approach to antihypertensive therapy in pregnant women.
Umans
J G
JG
Division of Nephrology and Hypertension, Georgetown University Medical Center, 6PHC, 3800 Reservoir Road, NW, Washington, DC 20007, USA. jgu@georgetown.edu
Lindheimer
M D
MD
D000959:Antihypertensive Agents / Q000627:therapeutic use*; D005260:Female; D005333:Fetus / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects / Q000502:physiology; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D008429:Maternal Welfare; D011247:Pregnancy / Q000187:drug effects; D011249:Pregnancy Complications, Cardiovascular / Q000188:drug therapy*; D012307:Risk Factors
D000959:Antihypertensive Agents